TRBV6-5: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

Target Name: TRBV6-5

NCBI ID: G28602

TRBV6-5

TRBV6-5: A Non-Coding RNA Molecule as A Potential Drug Target and Biomarker

TRBV6-5 (TcRBV13S1) is a non-coding RNA molecule that has been identified as a potential drug target (also known as a biomarker) for the treatment of various diseases, including cancer. Its unique structure and expression patterns have made it an attractive target for researchers to study and develop new treatments.

TRBV6-5 is a part of the T cell receptor (TCR) gene family, which is responsible for the development and activation of T cells, a crucial immune system cell that plays a key role in fighting off infections and diseases. The TCR is a protein that consists of a constant region, a variable region, and a short cytoplasmic tail. The cytoplasmic tail of TRBV6-5 is composed of 13 exons that are responsible for its unique structure and function.

TRBV6-5 has been shown to play a critical role in the development and progression of various diseases, including cancer. Its expression has been observed in various tissues, including the blood, spleen, and lymph nodes, and has been associated with the development of Various diseases, including cancer.

One of the key features of TRBV6-5 is its ability to interact with other molecules in the immune system. It has been shown to interact with the protein PD-L1, which is a negative regulator of the immune response. PD-L1 has been shown to play a critical role in the regulation of cancer growth and has been identified as a potential drug target for cancer treatment.

In addition to its potential as a drug target, TRBV6-5 has also been shown to have potential as a biomarker. Its expression has also been used as a diagnostic marker for various diseases, including cancer. Its expression has also been used to monitor the effectiveness of cancer treatments and to predict the risk of disease recurrence.

TRBV6-5's unique structure and expression patterns have made it an attractive target for researchers to study and develop new treatments. Its ability to interact with other molecules in the immune system and its potential as a drug and biomarker make it a promising target for the development of new treatments for a variety of diseases.

In conclusion, TRBV6-5 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for the treatment of various diseases, including cancer. Its unique structure and expression patterns make it an attractive target for researchers to study and develop new treatments. Further research is needed to fully understand its potential and to develop safe and effective treatments.

Protein Name: T Cell Receptor Beta Variable 6-5

Functions: V region of the variable domain of T cell receptor (TR) beta chain that participates in the antigen recognition (PubMed:24600447). Alpha-beta T cell receptors are antigen specific receptors which are essential to the immune response and are present on the cell surface of T lymphocytes. Recognize peptide-major histocompatibility (MH) (pMH) complexes that are displayed by antigen presenting cells (APC), a prerequisite for efficient T cell adaptive immunity against pathogens (PubMed:25493333). Binding of alpha-beta TR to pMH complex initiates TR-CD3 clustering on the cell surface and intracellular activation of LCK that phosphorylates the ITAM motifs of CD3G, CD3D, CD3E and CD247 enabling the recruitment of ZAP70. In turn ZAP70 phosphorylates LAT, which recruits numerous signaling molecules to form the LAT signalosome. The LAT signalosome propagates signal branching to three major signaling pathways, the calcium, the mitogen-activated protein kinase (MAPK) kinase and the nuclear factor NF-kappa-B (NF-kB) pathways, leading to the mobilization of transcription factors that are critical for gene expression and essential for T cell growth and differentiation (PubMed:23524462). The T cell repertoire is generated in the thymus, by V-(D)-J rearrangement. This repertoire is then shaped by intrathymic selection events to generate a peripheral T cell pool of self-MH restricted, non-autoaggressive T cells. Post-thymic interaction of alpha-beta TR with the pMH complexes shapes TR structural and functional avidity (PubMed:15040585)

The "TRBV6-5 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TRBV6-5 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets